Evidence map›Paper›PMID 39716939›Full record

Trial reportESC heart failure2025

Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF.

Andrew P Ambrosy, Andrew J Sauer, Shachi Patel, Sheryl L Windsor, Barry A Borlaug, Mansoor Husain, Silvio E Inzucchi, Dalane W Kitzman, Darren K McGuire, Sanjiv J Shah and 3 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andrew P AmbrosyDepartment of Cardiology, Kaiser Permanente, San Francisco, California, USA.
Andrew J SauerSaint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Shachi PatelSaint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Sheryl L WindsorSaint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Barry A BorlaugDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Mansoor HusainTed Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University of Toronto, Toronto, Canada.
Silvio E InzucchiYale School of Medicine, New Haven, Connecticut, USA.
Dalane W KitzmanSections on Cardiovascular Medicine and Geriatrics, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Darren K McGuireSouthwestern Medical Center and Parkland Health and Hospital System, University of Texas, Dallas, Texas, USA.
Sanjiv J ShahDivision of Cardiology, Department of Medicine, and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Kavita SharmaSchool of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Guillermo UmpierrezEmory University, Atlanta, Georgia, USA.
Mikhail N KosiborodSaint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.

Funding

Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI Kevan C Herold, GERALD I SHULMAN · 1993 to 2026
$44.0M
AstraZenecaNIDDK NIH HHS P30 DK045735
6 · The paper itself

Abstract

aimsSodium-glucose co-transporter-2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in HF, complicates HF management and is strongly linked to worse health status. This study aimed to assess whether the treatment effects of dapagliflozin on health status vary based on estimated glomerular filtration rate (eGFR). METHODS AND

resultsWe conducted a pooled participant-level analysis of two double-blind, randomized trials, DEFINE-HF (n = 236) and PRESERVED-HF (n = 324), which evaluated dapagliflozin versus placebo. Both multicentre studies enrolled adults with HF, New York Heart Association Class II or higher, elevated natriuretic peptides, and an EF < 40% in DEFINE-HF or >45% in PRESERVED-HF. The primary exposure was eGFR. The main outcome was the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at 12 weeks. Across both trials, there were 583 (99.3%) participants with a baseline eGFR. The median (25th, 75th) eGFR was 59 (46, 77) mL/min/1.73 m

conclusionsDapagliflozin led to early and clinically meaningful improvements in health status in HF patients, regardless of EF or baseline eGFR.

Indexed as

Benzhydryl CompoundsGlomerular Filtration RateGlucosidesHealth StatusHeart FailureStroke VolumeAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsdapagliflozinejection fractionhealth statusheart failurerenal function

Identifiers

PMID39716939
PMCPMC12055384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.